Key Points
- Teva VP Richard Daniell sold 115,468 shares on Dec. 9 at an average price of $28.68 for about $3.31 million, leaving him with 48,384 shares — a 70.47% reduction in his direct stake.
- Multiple analysts have recently raised ratings and price targets (Barclays/Scotiabank $35, BofA $32, Goldman $31, JPMorgan $28), leaving an average consensus rating of "Buy" and an average price target of $30.25.
- Teva shares opened at $30.16 (near a 12‑month high of $30.20), the company has a market cap of $34.59 billion and a PE of 50.27, and roughly 54% of the stock is held by institutional investors.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Teva Pharmaceutical Industries Trading Up 1.2%
Shares of NYSE:TEVA opened at $30.16 on Friday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $30.20. The business has a 50 day moving average of $23.23 and a 200-day moving average of $19.51. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock has a market cap of $34.59 billion, a PE ratio of 50.27, a P/E/G ratio of 1.77 and a beta of 0.67.
Analysts Set New Price Targets
Several analysts recently issued reports on TEVA shares. Barclays initiated coverage on Teva Pharmaceutical Industries in a research note on Tuesday. They issued an "overweight" rating and a $35.00 price target for the company. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a "sector outperform" rating and a $35.00 target price on the stock. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Monday. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an "overweight" rating in a research note on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $30.25.
Get Our Latest Stock Analysis on Teva Pharmaceutical Industries
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Bourgeon Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 100.7% in the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock valued at $12,134,000 after buying an additional 363,252 shares during the last quarter. Amundi increased its position in Teva Pharmaceutical Industries by 18.5% in the 1st quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after acquiring an additional 105,846 shares during the period. IFM Investors Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock valued at $3,797,000 after acquiring an additional 19,447 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 5.5% during the second quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company's stock worth $12,062,000 after purchasing an additional 37,455 shares during the period. Finally, Jump Financial LLC grew its stake in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock worth $20,373,000 after purchasing an additional 838,423 shares during the last quarter. 54.05% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
